Tuberculosis detection kit DR1019

pneumoniaCEAprotease

SCC is mainly used in dynamic monitoring with cancer and assists diagnosis of disease progression or therapeutic effect, but its concentration is not directly correlated with tumor size, growth, malignancy and grade/stage. For some benign diseases such as hepatitis, cirrhosis, pneumonia, and tuberculosis and so on, SCC also rise. It cannot be used for cancer screening in the general population, especially early and definite diagnosis. Product Description SCC is a group of glycoprotein of serine/cysteine protease inhibitor family, with molecular weight of 45,000 Daltons. SCC was originally isolated from squamous cell carcinoma by Kato and etc. It is composed of at least 10 different subunits of isoelectric points. In the diagnosis of cervical cancer: SCC sensitivity of primary cervical squamous cell carcinoma was 44% -69%; of recurrent cancer was 67% to 100% , and specificity is 90% -96%; its serum level is related with tumor development, extent of violations and metastasis. After radical operation of cervical cancer, SCC decreased significantly; SCC can prompt early recurrence, for 50% of patients, elevated level of SCC is 2-5 months earlier than the clinical diagnosis, which can be applied as an independent risk factor. SCC assists the diagnosis of lung squamous cell carcinoma. It is related with SCC tumor progression. Combined with CA125, CYFRA21-1 and CEA, it will improve the diagnostic sensitivity of lung cancer. For ESCC prediction, SCC increased with progression of the disease. For patients with advanced disease, the sensitivity can be up to 73%.